Doubling its base of healthcare professionals, the leading e-prescription platform will accelerate the expansion of solutions connecting professionals and patients across the healthcare journey
Mevo, Brazil's leading e-prescription healthtech, announced today a US$18m (BRL 95M) funding round led by Prosus, with strong participation from existing shareholders including Matrix, Jefferson River, and Floating Point. This new capital is on the heels of Mevo’s US$24m USD Series B in 2024, as markets validate the strength of the company's technology platform and value proposition.
The investment will accelerate Mevo’s mission to use the e-prescription as the strategic entry point to a more connected patient journey – streamlining steps such as exam scheduling, integration with patient support programs, and seamless online medication fulfillment. “At scale, this creates a powerful foundation for ecosystem growth, connecting patients to a broader range of services across the care journey. The company projects 20 million patients will be treated via Mevo’s digital prescriptions in 2026 alone”, says Pedro Dias, CEO of Mevo.
Founded in 2017, Mevo began as a digital prescription platform. The innovation addresses a major gap in Brazil’s healthcare system, where more than 150 million people manage roughly one billion handwritten prescriptions each year, creating inefficiencies that limit the development of more integrated patient services.
Today, Mevo is continuing to modernize this landscape. Its growth strategy is built on three pillars: its core e-prescription service for both large-scale healthcare institutions and individual practitioners; Mevo Shop, a patient-facing portal for exam scheduling and online pharmacy orders; and a dedicated vertical for pharmaceutical industry partners.
The company’s institutional strength is a key differentiator in the Brazilian market, with its platform already integrated into more than 1,100 healthcare institutions and seven major health insurance providers, together covering around 30% of Brazil’s private healthcare market. Today, Mevo is the platform of choice for 9 of the 10 best hospitals in Brazil, according to the 2026 Newsweek rankings, and has been expanding across key segments of the healthcare ecosystem. Among private practitioners, the company has significantly increased its presence since the Series B round, expanding its base of individual prescribers five times following the acquisition of Receita Digital, a key competitor in the segment.
In parallel, Mevo has accelerated the growth of its pharmacy and fulfillment vertical. Through Mevo Shop, the platform is now integrated with more than 11 major pharmacy chains and approximately 1,600 retail locations, primarily concentrated in Brazil’s Southeast and South regions.
The company has also expanded its pharmaceutical industry solutions vertical, launched in late 2024, which connects pharmaceutical companies with physicians through secure medical education initiatives while enabling patients to access discounts and support programs. This vertical has quickly become an important growth driver for Mevo, already serving 20 recurring enterprise clients and with more than double-digit projects currently under negotiation.
For Prosus, this new investment reinforces its conviction in Mevo’s operational excellence and category-leadership potential: “Brazil has consistently shown a strong appetite for digital platforms — from fintech to mobility to food delivery — and we believe healthcare is the next major frontier. Mevo sits at the center of that shift, combining deep institutional partnerships with a product that simplifies how care is delivered. The team’s strong execution gives us confidence in their ability to scale the platform across Brazil. We’re excited to continue supporting the founders in this next phase of growth,” said Henrique Iwamoto, Chief Investment Officer, Prosus Latin America.
Other investors share the same perspective. TJ Parker, general partner at Matrix, added, “It’s been inspiring to see Mevo grow since our first investment. We’re pleased to continue supporting the team as it continues to transform how prescriptions are delivered in Brazil and build a platform that organizes the entire patient journey. Their track record of execution and market leadership makes this follow-on investment an easy decision.”
About Prosus
Prosus is the power behind the world’s leading lifestyle ecommerce brands, across Europe, India, and Latin America, unlocking an AI-first world for our 2 billion customers.
The Prosus technology ecosystem spans food delivery, payments, classifieds, travel, events, and mobility. Our integrated approach enhances user engagement and creates the foundation for unprecedented AI capabilities through proprietary data and cross-service intelligence.
Through Prosus Ventures, we invest in companies which inspire and support the Prosus ecosystem. We search for new opportunities at the leading edge of AI and ecommerce, the digital AI workforce and in frontier technologies, such as robotics, drones and synbio.
The team actively backs exceptional entrepreneurs who are using technology to improve people’s everyday lives.
To find out more, please visit www.prosus.com.
